

# Conjunctivochalasis: A Systemic Review

## ABSTRACT

Conjunctivochalasis is defined as a redundant, nonedematous conjunctiva that causes a wide variety of symptoms ranging from completely asymptomatic, to worsening of an unstable tear film, and when severe, a real mechanical disruption of tear flow.

Due to the fact that conjunctivochalasis can be asymptomatic, it is often overlooked by the physician and it is classified as a normal variant of the eye due to the aging process. However, it must be kept in mind as a possibility for the origin of ocular irritation and tearing; and when severe enough it may be a cause of blurred vision, mucous discharge, dryness, ocular fatigue, subconjunctival hemorrhage, and eye stiffness upon awakening. This redundant conjunctiva can often be seen and frequently overlooked after tightening of lateral canthal tendon.

The symptoms are nonspecific and the onset may be insidious and uncertain, often confused with dry eye ones. Initial symptoms include foreign body sensation, burning, dry eyes and discomfort. Disorder of tear meniscus, impaired tear distribution and punctal occlusion play a role in the onset of symptoms. Slit lamp biomicroscopy shows a prolapse of the conjunctiva over the lower lid margin in temporal, medial or nasal regions. This prolapsed conjunctiva causes a disruption of tear movement and outflow through the inferior lacrimal punctum, resulting in epiphora.

Although the etiopathogenesis of the disease has not yet been clearly understood, several theories have been proposed. According to the mechanical theory, age-related mechanical changes in the conjunctiva lead to a chronic obstruction of the lymphatic flow and lymphatic dilatation after this chronic obstruction leads to conjunctivochalasis. According to the inflammatory theory, the degradation of the extracellular matrix destruction in the tear increases as a result of disturbance in tear distribution. and this increase causes inflammatory changes resulting in conjunctival laxity. [Please rephrase!]

While there is no need for treatment in the non-symptomatic group in the management of conjunctivosalasis [check spelling], artificial tears and topical steroid treatment are the medical treatment options in symptomatic cases. [6] Surgical treatment is required in patients who do not respond to medical treatment.

Keywords: conjunctivochalasis, dry eye, epiphora, cauter?, argon laser, reduntant conjunctiva  
The keywords are better presented in alphabetical order

## INTRODUCTION

Conjunctivochalasis is defined as a redundant, nonedematous conjunctiva that causes a wide variety of symptoms ranging from completely asymptomatic, to worsening of an unstable tear film, and when severe, a real mechanical disruption of tear flow. [1]


Due to the fact that conjunctivochalasis (CCh) can be asymptomatic, it is often overlooked by the physician and it is classified as a normal variant of the eye due to the aging process. However, it must be kept in mind as a possibility for the origin of ocular irritation and tearing; and when severe enough it may be a cause of blurred vision, mucous discharge, dryness, ocular fatigue, subconjunctival

19 hemorrhage, and eye stiffness upon awakening. This redundant conjunctiva can often be seen and  
20 frequently overlooked after tightening of lateral canthal tendon. [2]

21 Conjunctivochalasis is usually bilateral, involving most commonly the inferotemporal conjunctiva,  
22 that may cause disruption of the inferior tear meniscus. It may present as loose superior conjunctiva,  
23 although it is less common.

24 The symptoms are nonspecific and the onset may be insidious and uncertain, often confused with  
25 dry eye ones. Initial symptoms include foreign body sensation, burning, dry eyes and discomfort.  
26 Disorder of tear meniscus, impaired tear distribution and punctal occlusion play a role in the onset of  
27 symptoms. [3] Slit lamp biomicroscopy shows a prolapse of the conjunctiva over the lower lid  
28 margin in temporal, medial or nasal regions. [Figure 1,2] This prolapsed conjunctiva causes a  
29 disruption of tear movement and outflow through the inferior lacrimal punctum, resulting in  
30 epiphora. [Figure 3] Confusion arises in the management of this entity because there are other  
31 diseases and conditions that produce tearing and ocular irritation and must be ruled out as a  
32 causative agent of the tear flow disruption and tear instability (Dry Eye Syndrome,  
33 Keratoconjunctivitis Sicca, ocular allergies, thyroid eye disease, among others).

34




35

36 **FIGURE 1:** Prolapse of the conjunctiva over the lower lid margin in temporal region

37


38



39

40 **FIGURE 2:** Prolapse of the conjunctiva over the lower lid margin in medial and temporal region

41



42

43 **FIGURE 3:** Prolapsed conjunctiva causes a disruption of tear movement and outflow through the  
44 inferior lacrimal punctum, resulting in epiphora.

45

46 Although the etiopathogenesis of the disease has not yet been clearly understood, several  
47 theories have been proposed. According to the mechanical theory, age-related mechanical changes in  
48 the conjunctiva lead to a chronic obstruction of the lymphatic flow and lymphatic dilatation after this  
49 chronic obstruction leads to conjunctivochalasis. [4]

50 According to the inflammatory theory, the degradation of the extracellular matrix destruction in  
51 the tear increases as a result of disturbance in tear distribution- and this increase causes [ this

52 sentence needs to be rephrased please check your punctuation marks too.] inflammatory changes  
53 resulting in conjunctival laxity.

54 Previous studies in which histopathology of conjunctiva chalasis was evaluated by light  
55 microscopy, stromal lymphangiectasis, stromal edema, disintegration of elastic fibers, elastosis and  
56 chronic nongranulomatous inflammation were reported. Electron microscopy revealed that  
57 intercellular conjunctival stenosis and concomitant stromal elastin were observed. [5] While there is  
58 no need for treatment in the non-symptomatic group in the management of conjunctivo salasis,  
59 artificial tears and topical steroid treatment are the medical treatment options in symptomatic cases.  
60 [6] Surgical treatment is required in patients who do not respond to medical treatment.

61

## 62 CONJUNTIVOCHALASIS

### 63 Definition

64 Conjunctivochalasis was first described by Braunschweig in 1921. [7] After Duke - Elder evaluated  
65 it as a conjunctival hyperplasia requiring surgical excision or electrocoagulation, Liu et al. [4] in 1986,  
66 they described this disease as loose, non-edematous excess bulbar conjunctival tissue protruding  
67 from the eyelid by entering the globe between the lower eyelid. [8]

68

### 69 Symptoms

70 In conjunctivochalasis patients, loose conjunctival tissue may not cause any symptoms, but excess  
71 conjunctival tissue may cause some symptoms by causing friction on conjunctival surface or between  
72 conjunctiva and cornea. [2] Blurred vision, watering, pain, stinging, burning, foreign body sensation,  
73 such as complaints of loose conjunctival tissue contributes to disrupt the tear meniscus. [9]

74 In these patients, where the tear distribution on the ocular surface is disrupted, although Schirmer  
75 test and tear break time measurements show that there is no lack of quality and quantity of tears,  
76 dry eye-like symptoms may occur.

77 Increased symptoms such as pain and blurred vision may be associated with increased conjunctival  
78 folds on the lower eyelid edge during activities that require prolonged stay in the downward  
79 position, such as reading. [10] In a study comparing dry eye with CCh cases without aqueous tear  
80 deficiency and CCh cases in terms of ocular surface symptoms, it was found that the symptoms  
81 increased in the later hours of the day in patients with dry eye, while the other group patients stated  
82 that they woke up and had more dryness during the reading. Increased inflammatory cytokines in  
83 tears due to decreased tear clearance during sleep have been thought to be the cause of symptoms  
84 that become evident when awakened. [11]

85

86

87

88

89

## 90 Etiopathogenesis and Histopathological Changes

91 No true aetiology is known for conjunctivochalasis. Senile changes involving the subcutaneous,  
92 elastic or supporting tissue in the conjunctiva was suggested as the cause. Eye rubbing, mechanical  
93 irritation or trauma to conjunctiva, and abnormal eyelid position were all implicated. [12] Some  
94 investigators have suggested that the addition of some inflammatory processes to age-related  
95 changes in the structure of conjunctival tissue plays a role in the pathogenesis of the disease. [5]  
96 While the mechanical effect of the eyelids caused by the clipping movement contributes to these  
97 structural changes, local trauma, ultraviolet radiation and delayed tear clearance can accelerate the  
98 inflammatory process. [13,14]

99 Almeida et al. In their cohort study, they investigated the relationship between autoimmune  
100 thyroid diseases and CCh, and concluded that autoimmune thyroid disease was a predisposing risk  
101 factor for CCh. [15]

102 Although most of the patients with chronic disease suffer from irritations irritations, there are  
103 also researchers who suggest that dry eye plays an important role in the etiology. It has been argued  
104 that dryness of the ocular surface increases the mechanical effect of the eyelids on the conjunctiva  
105 and the amount of inflammation mediators released. [9]

106 Hoh et al. While concluded that conjunctivochalasis contributes to the development of dry eye,  
107 the clinical and physiopathological role of conjunctivochalasis in dry eye disease due to aqueous tear  
108 insufficiency is not clearly known. [10,16]

109 Francis et al., in a prospective clinical and histopathological study of 29 patients, 22 of them  
110 showed normal conjunctival histology, while 4 specimens showed inflammatory changes, and 3  
111 specimens showed elastosis. They concluded and hypothesized that the etiology is multifactorial,  
112 including local trauma, UV radiation and delayed tear clearance as triggers of the disease. [17]

113 Harbiyeli II et al. showed mechanical and inflammatory factors induce development of CCh, and  
114 signs associated with these factors can be detected with light and electron microscopy of  
115 conjunctival tissue. [18]

116

117 Kalin et al. In 7 patients with whom they could not find any other reason, conjunctiva olchalasis  
118 was named as "chronic localized conjunctival chemosis. [19]

119 Kheirkhah et al. in their study in the upper location CSA cases, upper bulbar conjunctival slack in the  
120 conjunctival tissue is not due to the excess of the conjunctival tissue, depending on insufficient  
121 function of the conjunctiva and sclera caused by the loss of adhesion suggested that this situation.  
122 [20]

123 There are two main theories about the mechanism that causes conjunctival tissue changes in the  
124 development of conjunctivosalasis. [9] One of them is the mechanical theory which argues that  
125 chronic obstruction caused by age-related mechanical changes in the conjunctival tissue plays the  
126 most important role in the pathophysiology of the disease, while the other is the extracellular matrix  
127 destruction mediated by tear cytokines mediated by increased tear cytokines due to delayed tear  
128 clearance. [21]

129

130 **Inflammatory Theory**

131 Inflammation of the ocular surface in conjunctiva **alchhalasis (check spelling)** is manifested by  
132 inflammatory cell infiltration in the conjunctival epithelium and stroma, **and tears??** are also  
133 affected. Increased collagenolytic activity and degeneration of elastic fibers are changes in the  
134 extracellular components of the conjunctival tissue. [5] Ocular surface inflammation has been  
135 suggested to play a role in the development of this degenerative process. It is thought that high  
136 inflammatory cytokines in the tears are released from the conjunctival epithelium or from the  
137 endothelium in the conjunctival vessels due to blinking and ocular movements and trauma to the  
138 loose conjunctiva. [22]

139 Clogging of the tear meniscus and punctum with excess conjunctival tissue causes delayed tear  
140 clearance. Delayed tear clearance increases the amount of cytokines in tears. [10]

141 Elevated levels of TNF-Alpha, IL-1, IL-6, IL-8 and IL-12 lead to increased levels of matrix  
142 metalloproteinase (MMP) involved in conjunctival epithelial and stromal connective tissue  
143 degradation and restructuring. The inflammatory response caused by elevated metalloproteinase  
144 levels, particularly MMP 3 and MMP 9, results in conjunctival elastosis. The role of increased  
145 oxidative stress due to insufficient function of antioxidant enzymes is known in age-related dry eye  
146 syndrome and skin aging. In a study on the role of oxidative stress in conjunctivochalasis, 8-hydroxy-  
147 2-deoxyguanosine (8-OHdG) showing oxidative stress-related DNA damage and N-hexanoyl-lysine  
148 (HEL) levels were evaluated as oxidative stress markers. In conjunctival samples, the number of  
149 conjunctival cells positively stained with N-hexanoyl-lysine and 8-hydroxy-2-deoxyguanosine and the  
150 HEL levels measured in tears were higher in the conjunctivochalasis group than in the control group,  
151 increased oxidative stress in etiopathogenesis. [23]

152 Acera A et al. find concentration of pro-MMP-9 was significantly higher in the  
153 conjunctivochalasis eyes than in the healthy controls in their study. [24]

154 Zhang XR et al. demonstrated the lamina propria of the bulbar conjunctiva mildly chronic  
155 inflammatory changes accompanied by a large number of lymphangiectasia who has  
156 conjunctivochalasis. They suggested bulbar conjunctival lymphangiectasia may be one of the reasons  
157 for the conjunctivochalasis. [4]

158 Jia YL et al. investigated the potential role of MAPK signaling pathways in conjunctivochalasis  
159 (CCH). They showed that the expression of p-ERK, p-JNK, and p-p38 in CCH conjunctiva was  
160 significantly higher than that in control group. The expression of p38 MAPK, JNK, and ERK proteins in  
161 CCH fibroblasts was significantly higher than that in control group. The total expression of MAPK  
162 mRNA in CCH fibroblasts was significantly higher than that in control group. The activated forms of  
163 p38 MAPK, JNK, and ERK proteins and mRNAs might up-regulate the expression of MMPs in CCH  
164 loose conjunctival tissue and fibroblasts, causing the degradation of collagen fibers and elastic fibers  
165 and promoting the occurrence of CCH. [25]

166 Li et al. showed overexpression of MMP-1 and MMP-3 mRNA in tissue cultured  
167 conjunctivochalasis fibroblasts, versus normal human conjunctival fibroblasts. Further studies  
168 showed that inflammatory mediators TNF- $\alpha$  and IL-1 $\beta$  may increase the expression of MMP-1 and  
169 MMP-3 in conjunctivochalasis fibroblasts. Other inflammatory cytokines were also found in increased  
170 amounts in tear film of conjunctivochalasis patients (IL6 and IL8). After these observations, they  
171 concluded that the interaction of MMPs and their inhibitors, in a broken equilibrium may lead to a  
172 manifestation of a redundant conjunctiva with increased laxity. [26]

173 Gan JY et al. analysed the literature, they found elastic fibers was a complex protein molecule  
174 from the structure and composition; the degradation of elastic fibers was one of the



175 histopathological features of the disease; the vast majority of the factors related to the pathogenesis  
176 of CCh ultimately pointed to abnormal elastic fibers. By reasonably speculating, they considered that  
177 abnormal elastic fibers cause the conjunctival relaxation. In conclusion, they hypothesized that  
178 elastic fibers play an important role in the pathogenesis of CCh. Studies on the mechanism of  
179 synthesis, degradation of elastic fibers are helpful to clarify the pathogenesis of the disease and to  
180 find effective treatment methods. [27]

### 181 **Mechanical Theory**

182 Another factor that plays a role in the development of conjunctivochalasis is age-related  
183 degenerative structural changes in the conjunctiva. [28] In addition to studies suggesting that  
184 inflammatory changes occurring in conjunctival epithelium and stroma lead to loose conjunctival  
185 tissue formation, there are also researchers who hypothesize that histopathological changes are only  
186 associated with conjunctival stroma and protect the structure of conjunctival epithelium. [29]

187 Watanabe et al. demonstrated subconjunctival microscopic telangiectasia in 4 of 39 specimens taken  
188 from patients with severe conjunctivochalasis, with no evidence of inflammation. They also noted  
189 fragmented elastic fibers and sparse assemblages of collagen fibers in 44 specimens. They concluded  
190 that mechanical forces between the lower eyelid and conjunctiva gradually impaired lymphatic flow,  
191 resulting in lymphatic dilation and clinically redundant conjunctiva. [3] Even though there is little to  
192 no histopathologic evidence to support inflammation as a major contributor to conjunctivochalasis,  
193 mechanistic evidence suggests a shift in the normal balance of the conjunctival matrix  
194 metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs).

195 Poh S et al. showed that meibomian gland dysfunction and female gender were associated with  
196 lower tear meniscus area , while older age was associated with increased severity of  
197 conjunctivochalasis. [30]

198 Hashemian H et al. evaluated the histopathologic changes in the conjunctiva of patients with  
199 conjunctivochalasis (CCh) compared to age-matched controls.They showed that there were no  
200 significant differences between the two groups (27 patients with CCh and 16 control group) in terms  
201 of elastosis, fibrosis, lymphangiectasia, or infiltration of inflammatory cells in conjunctival stroma.  
202 Therefore,they suggested the primary pathology of CCh may not be within the conjunctiva itself.  
203 Instead, loose attachment of the conjunctiva to the underlying tissue may be the reason for the  
204 redundant folds in the bulbar conjunctiva. [31]

205

206 It has been suggested that these changes occur as a result of mechanical forces between the lower  
207 eyelid and the conjunctiva disrupting the lymphatic flow in the conjunctiva with advancing age. [32]

208

### 209 **Clinical Findings**

210 Conjunctivalchalasis( check spelling) is usually detected bilaterally by the presence of excess  
211 conjunctival tissue located nasally, centrally, or temporally around the lower eyelid. [10]

212 Depending on the amount of loose conjunctival tissue, conjunctival folds may be remarkable at  
213 first glance, and in some cases it may be necessary to push the conjunctiva over the eyelid to see the  
214 folds. On examination, decreased tear break time, corneal and conjunctival staining, delayed tear  
215 clearance, eyelid edge erosions, impaired tear meniscus, punctum blistering, subconjunctival

216 haemorrhage are among the findings. [33] Pinguecula and loose eyelid syndrome are other ocular  
217 findings that can be seen in patients with conjunctivochalasis.

218 In the mild form of the disease, the tear film layer deteriorates due to the effect of the tear  
219 meniscus, while the tear clearance decreases in the next stage. In more serious forms of the disease,  
220 conjunctival dryness may be seen due to external exposure of the dellen formation and the  
221 conjunctiva overhanging the eyelid edge due to tear dispersion. [34]

222 Loose conjunctival tissue accumulates at the edge of the lower eyelid, disrupting the tear  
223 meniscus and adversely affects tear dispersion. In addition, this excess in the conjunctival tissue  
224 causes inflammation at the eyelid edge due to its mechanical effect. Inflammation of the valve edge  
225 causes meibomian gland dysfunction and the lipid layer of the tear. [10] The reduced tear break up  
226 time detected in these patients can be attributed to these changes in tear content and distribution.  
227 Corneal and conjunctival staining is another clinical finding related to tear content and distribution in  
228 the distribution. [5,9] Fluorescein and Rose-Bengal staining and corneal staining, as well as staining  
229 of conjunctival tissue folds can be shown.

230 In a study investigating the effect of tear inflammatory cytokines on ocular surface findings in  
231 conjunctivochalasis patients, the amount of inflammatory cytokine in tears was shown to be  
232 associated with corneal epithelial damage and corneal staining. [5]

233 Injury of the conjunctival epithelium, meibomian gland dysfunction as well as the friction effect  
234 caused by pinching between the eyeball and the lower eyelid. In addition to the deterioration of the  
235 tear meniscus, anatomical changes in the punctum also play a role in mechanically reducing the  
236 transition of the tear to the canalicular system. [10] Another reason for the tear overflow in these  
237 patients is that insufficient meibum does not show an effective lipid barrier function. Delayed tear  
238 clearance can be detected in these patients, where the complaint of watering is in the foreground.

239 Variable localization of loose conjunctival tissue on the sclera allows subconjunctival vessels to  
240 easily rupture by rubbing or blinking the eye. Another cause of subconjunctival hemorrhage is  
241 increased oxidative stress related vasculopathy. [5]

242 Francis et al. [5] emphasized that there were no ocular findings such as conjunctival staining, eyelid  
243 edge erosion, punctum swelling, subconjunctival hemorrhage in conjunctivochalasis patients with  
244 irrigated complaints, they suggested that these findings were related to drying on the ocular surface.  
245 [35]

246 Although CCh is frequently seen in the temporal conjunctival tissue of the lower eyelid, it can also  
247 be seen in the nasal and upper conjunctival tissues. Loose and excess conjunctival tissue in the upper  
248 bulbar conjunctiva may cause a clinical picture similar to superior limbic keratoconjunctivitis (SLK).  
249 Although the relationship between SLK and CCh has been emphasized in some studies, the  
250 pathological significance of this relationship is still unclear. [36] The loose upper bulbar conjunctiva, a  
251 characteristic clinical manifestation of SLK, has been proposed as evidence supporting the theory of  
252 mechanical friction in the pathogenesis of SLK, as in CCh. [37]

253 Cases with conjunctivochalasis located nasally are characterized by different effects of loose  
254 conjunctival tissue on punctum and tear drainage mechanism.

255

256

257 **Diagnosis**



258 CCh is one of the most common misdiagnosed ocular surface disease. Non-specific symptoms  
259 along with intermittent findings of conjunctival edema often lead to misdiagnosis. Due to fluctuation  
260 in findings of disease process, several clinical exams may be required to confirm the diagnosis. Many  
261 patients are first diagnosed when epiphora develops due to blocked puncta caused by redundant  
262 conjunctiva. Diagnosis of CCh is mainly clinical.

263 Slit lamp biomicroscopy shows prolapsed or folds of conjunctiva in temporal, nasal or central part  
264 of lower lid-margin. Presence of redundant conjunctiva over lower lid margin, reduced tear film  
265 break up time (BUT), anterior migration of muco-cutaneous junction caused by overflow of aqueous  
266 tears due to obliteration of tear meniscus suggests CCh. Prolapsed conjunctiva causes a disruption of  
267 tear movement and outflow through inferior lacrimal punctum resulting in epiphora.

268 Diagnosis of CCh is mainly clinical but also some medical device can be used.. Gumus K et al.  
269 showed that the AS-OCT is a useful and reproducible instrument to measure the cross-sectional area  
270 of conjunctiva prolapsing into the tear meniscus of patients with conjunctivochalasis. The method  
271 can monitor effectiveness of thermoreduction of conjunctivochalasis. [38]

272 The differential diagnosis can be difficult, as common signs and symptoms may be misleading.  
273 One tool that may help is tear film osmolarity. In symptomatic patients with a low osmolarity  
274 reading, conditions other than dry eye may be present.

275

276 Pain is another differentiator—patients with ocular surface disease often complain of chronic  
277 irritation; however, those with conjunctivochalasis complain of pain specifically in the affected  
278 area. Lastly, conjunctivochalasis may look similar to conjunctival chemosis, which often responds to  
279 antihistamines and anti-inflammatories. If you get a limited response from such therapies, consider  
280 conjunctivochalasis as the diagnosis. [39]

281

## 282 **MANAGEMENT AND TREATMENT**

283

284 Management must be individualize according to the severity and discomfort of each patient. No  
285 treatment is needed if the patient is asymptomatic. If a patient becomes mildly symptomatic, the  
286 clinician can start therapy with trials of lubrication and courses of topical corticosteroids. If patients  
287 continue to be in discomfort despite the medical management, surgical options can be taken into  
288 account.

289

### 290 **Medical Treatment**

291

292 If patients are asymptomatic then they can simply be observed. The finding of  
293 conjunctivochalasis alone does not warrant treatment.

294

295 When patients become symptomatic, the first line of treatment is medical. The goal is to reduce  
296 the effects of conjunctivochalasis, especially in regards to the disruption of the tear film. Lubricants  
297 tend to be the first-line medications, and while there have not been specific studies looking at  
298 different viscosities and their effects. However, more viscous drops are able to stay suspended on  
299 the surface of the conjunctiva and act in a fashion similar to a tear lake.

300

301 In severe cases in which the conjunctivochalasis causes the conjunctiva to be exposed even  
302 when the eyelids are closed, using artificial tear ointment and patching the eyes at night can be  
303 beneficial. [40] These patients may also need to use the ointment during the day if they have  
304 significant desiccation of the exposed conjunctiva.

305  
306 In addition to the medical approaches described, any other underlying inflammatory conjunctival  
307 conditions should be treated to assist in controlling the patient's symptoms. This includes treating  
308 allergic inflammation with topical antihistamines/mast cell stabilizers, and generally increased  
309 inflammation with topical steroids.[40] If patients remain symptomatic despite medical treatment,  
310 then surgery becomes a reasonable option.

## 311 312 **Surgical Treatment**

314 There are a number of different techniques that have been described to correct  
315 conjunctivochalasis. Some of these are minimally invasive and can be done in the office, while others  
316 require an operating room. According to the literature, Hughes was the first to successfully treat this  
317 condition by removing a section of the conjunctiva under the lower eyelid and closing the incision  
318 with a continuous black silk suture [41] Furthermore, suture fixation of the conjunctiva to the sclera  
319 with 6-0 Vicryl sutures has been described [42]. Additionally, electrocoagulation represents another  
320 method, which allows local inflammation to occur and the conjunctiva to attach to the  
321 subconjunctival Tenon's capsule [43]

322 Trivli and at al. previously reported another approach where, after surgical removal of the  
323 excess conjunctiva, preserved human amniotic membrane was placed over and sutured with a 10-0  
324 nylon continuous suture to the free conjunctival edges . [44] In the another study, similar to  
325 electrocoagulation,their surgical procedure using radiofrequencies achieves conjunctival shortening  
326 by burning excessive conjunctiva. The operation is performed in an outpatient clinic setting, is  
327 applicable to the conjunctival folds at any location, and patients experience minimal intraoperative  
328 and postoperative ocular irritation. [45]

## 329 330 **Cautery approaches:**

331 Some type of thermally-induced shrinkage or excision to get rid of the redundant folds of  
332 conjunctiva clinically visible and resting on the lower lid. One study described using thermocautery as  
333 a way to excise the excess conjunctiva at the slit lamp with results showing greater than 90-percent  
334 improvement in both subjective and objective findings. [46] Their technique involved grasping the  
335 redundant conjunctiva with smooth forceps and then excising the grasped portion with a handheld  
336 low-temp cautery. There was scarring noted postoperatively in 15 percent of their patients, but it  
337 didn't have any sequelae.

338  
339 Diana Muñoz, MD, and her colleagues in Bogota, Columbia, describe using a bipolar  
340 electrocautery forceps to apply the treatment directly to the symptomatic fold itself, which they  
341 identify by positive lissamine green staining. The procedure uses a traction suture through the  
342 inferior limbus to rotate the eye superiorly, so this may best be done in a controlled environment.  
343 After anesthetizing the area, the stained portion of conjunctiva is elevated and its base is grasped  
344 using the bipolar forceps. Energy is applied to the area directly at a rate of 30mA until "complete  
345 shrinkage" is achieved. The benefit of this technique is that you target the exact area the symptoms

346 are coming from for that individual patient, whether it is nasal, inferior or temporal. Dr. Muñoz's  
347 group noted that all of their patients had complete resolution of their symptoms without scar  
348 development. [47]

349 Nakasato S et al. showed that thermocautery is a simple and effective treatment for symptomatic  
350 inferior conjunctivochalasis. [48]

351 Trivli A. et al. supported that CCh treatment with radiofrequencies appears to be a safe, quick,  
352 and effective surgical technique. Operation time is less than 10 min and can be performed in an  
353 outpatient clinic. [45]

354 Chan TC et al. showed that superficial conjunctival cauterization is an effective technique for  
355 management of conjunctivochalasis in the short term. An increase in tear film lipid layer thickness  
356 along with a decrease in corneal thickness and volume were observed after surgical correction of  
357 conjunctivochalasis. [49]

358 Kim KH et al. showed that electrocauterization for conjunctivoplasty can be advantageous in  
359 terms of inflammation compared with simple suturing and excision. [50]

360 Jiang LH et al. showed that conjunctivochalasis line bipolar coagulation and removal of loose  
361 conjunctiva crescent with considerable effect, bipolar coagulation was significantly shorter operative  
362 time, a significant reduction in postoperative complications, surgical procedures easier. [51]

363 Haefliger IO et al. showed that gentle superficial cauterization of the inferior bulbar conjunctiva can  
364 induced significant reduction of a moderate conjunctivochalasis. [52]

365

#### 366 **Argon laser:**

367 Argon laser has also been used to "shrink" the redundant conjunctiva. In South Korea, Sangkyung  
368 Choi, MD, and his group describe using argon green laser treat the inferior conjunctiva. They apply  
369 approximately 100 burns during the treatment using "proper shrinkage" as the endpoint for their  
370 procedure. Their results showed a statistically significant improvement in the Ocular Surface Disease  
371 Index and in tear breakup time, improving from 9.2 seconds to 10.2 seconds. The treatments were  
372 more successful in mild and moderate cases. [53]

373 Yang J et al. used near-infrared laser thermal energy for conjunctivoplasty .In their study a fold of  
374 loose conjunctiva is grasped by a pair of forceps. The NIR laser light is delivered through an optical  
375 fiber and a laser line is aimed exactly on the conjunctival fold by a cylindrical lens. Ex vivo  
376 experiments using porcine eye was performed to investigate the induced shrinkage of conjunctiva  
377 and decide the optimal laser parameters. They found that up to 45% of conjunctiva shrinkage could  
378 be achieved. [54]

379

#### 380 **Incisional/glue approaches:**

381 In the operating room, the redundant conjunctiva can be removed in a number of ways  
382 previously described in the literature, including: simple excision with direct closure [55] injection of  
383 fibrin glue subconjunctivally, then pinching and excising; [56] as well as a technique in which a  
384 limbal peritomy is made with radial relaxing incisions, allowing the loose conjunctiva to be pulled  
385 anteriorly and excised with subsequent approximation of the cut edge of conjunctiva to the  
386 limbus.[57]

387 Kheirkhah A et al. showed that reinforcement of conjunctival adhesion onto the sclera by  
388 amniotic membrane with either fibrin glue or sutures and they suggested their procedure is  
389 effective in alleviating symptoms and signs in eyes with superior CCh. [58]

390 Wang X et al. evaluated the efficacy of two surgical methods (simple resection method, and  
391 resection and fixation method) for conjunctivochalasis. They found the recurrence rate of  
392 conjunctivochalasis was 6/16 in the simple resection group and 1/17 in the resection and fixation  
393 group on month 6 after operation, and there was significant difference ( $P = 0.039$ ). They said that  
394 both conjunctival resection and conjunctival resection with sclera fixation can effectively improve  
395 symptoms, but the latter 'resection and fixation method' has a lower recurrence rate. [59]

396 Santiago E et al. evaluated the outcomes of paste-pinch-cut conjunctivoplasty and cautery  
397 conjunctivoplasty for the treatment of symptomatic conjunctivochalasis. They found paste-pinch-cut  
398 and thermal cautery conjunctivoplasty are both safe and effective surgical treatments for the repair  
399 of conjunctivochalasis, with patients reporting greater improvement in symptoms after the cautery  
400 technique. [60]

401 Doss LR et al. described a new surgical technique for the repair of conjunctivochalasis (CCh) using  
402 subconjunctival injection of fibrin sealant followed by conjunctival resection. They suggested paste-  
403 pinch-cut conjunctivoplasty as a simple and an effective surgical treatment for the repair of CCh in  
404 symptomatic patients. [61]

405 Petris CK et al. supported that conjunctivoplasty using a simple medial conjunctival resection is an  
406 effective treatment for patients with epiphora secondary to conjunctivochalasis. [62]

407 Otaka I et al. showed that they treated conjunctivochalasis with conjunctival fixation to sclera,  
408 which strongly suggests that conjunctival folds are caused by the folding and the elevating of loosely  
409 adherent bulbar conjunctiva of the lower eyelid. [63]

410 Wang S et al. used a different surgery method which Conjunctival semiperitomy combined with  
411 gentle subconjunctival cauterization. They claimed that their procedure is a better therapy for  
412 conjunctivochalasis because it both resects the redundant conjunctiva and reestablishes the  
413 anatomic tight adhesion between the conjunctiva and the underlying sclera along the corneal limbus.  
414 [64]

415  
416 However, the most highly recommended surgical procedures not only excise the redundant folds  
417 of the conjunctiva or tighten it, but also reestablish the fornix. This is because if excision alone is  
418 performed, one of the possible complications is scarring leading to foreshortening of the fornix and  
419 the possible development of a cicatricial entropion. It's now believed that, when attempting to  
420 improve the function of the tear film, returning the depth of the fornix to its physiologic baseline is as  
421 important as removing the redundant conjunctiva. Scheffer Tseng, MD, and his group at Bascom  
422 Palmer showed that the tear reservoir in the inferior fornix will rapidly replenish the tear meniscus in  
423 normal patients, but that this process is blocked by the additional redundant conjunctiva in the fornix  
424 of conjunctivochalasis patients. [65] The group showed that repairing this surgically and deepening  
425 the inferior fornix reestablishes the normal function of the reservoir and thus provides better  
426 resolution of dry eye and ocular surface discomfort symptoms than excision alone.

427

428

429

430 Dr. Tseng describes being able to normalize the fornix during excision of the conjunctiva by making  
431 a crescentic excision of the loose inferior bulbar conjunctiva starting with a peritomy approximately 2  
432 mm posterior to the limbus. He excises all of the loose and thin conjunctival tissue, allowing the  
433 remaining conjunctiva to recess into the fornix. The bare scleral defect is then covered with  
434 cryopreserved amniotic membrane and anchored using either sutures [66] or fibrin glue. [67] Glue  
435 has become preferred due to less inflammation and better patient comfort. In a retrospective review  
436 by Dr. Tseng's group, there was significant improvement in dry-eye symptoms and clinical findings.  
437 An added benefit was that 56 percent of their patients who had a prior diagnosis of aqueous-  
438 deficient dry eye, which they termed aqueous tear deficiency, had normalized on their fluorescein  
439 clearance testing. [68] They hypothesize that the conjunctivochalasis caused so much disruption  
440 and blockage in the fornix that it had created an aqueous-deficient state.

441

442

443

#### 444 **CONCLUSION**

445

446 Ocular surface discomfort is a common and often frustrating condition for both patients and  
447 physicians. It's important to look at the entire ocular surface to diagnose and appropriately treat a  
448 patient's symptoms. With targeted treatment, there is a much better chance for success. To that  
449 effect, don't overlook the amount that conjunctivochalasis contributes to these symptoms. After  
450 trying conservative management with topical medications, if a patient is still symptomatic, then it's  
451 beneficial to take them to the operating room. While all of the surgical procedures discussed here  
452 produce great outcomes, excision of the redundant and loose conjunctiva with the attempt to  
453 reestablish the normal contour of the inferior fornix is a good choice.

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470 **REFERENCES**

- 471 1. Youm DJ, Kim JM, Choi CY. Simple surgical approach with high-frequency radio-wave  
472 electro-surgery for conjunctivochalasis. *Ophthalmology* 2010 Nov;117(11):2129-33. Epub 2010 Jun 8.
- 473 2. Meller D, Tseng SC. Conjunctivochalasis: literatür review and possible pathophysiology. *Surv*  
474 *Ophthalmol* 1998; 43: 225-232.
- 475 3. Watanabe A, Yokoi N, Kinoshita S, Hino Y, Tsuchihashi Y. Clinicopathologic study of  
476 conjunctivochalasis. *Cornea* 2004; 23: 294-298.
- 477 4. Zhang XR, Liu YX, Sheng X, Zhou HM, Han ZM, Fu ZX, Li QS, Xiang MH. Clinical observation of  
478 lymphangiectasis in conjunctivochalasis cases. *Zhonghua Yan Ke Za Zhi*. 2013 Jun;49(6):547-50.
- 479 5. Samantha K. Ward, Tais Hitomi Wakamatsu, Murat Dogru, Osama M. A. Ibrahim, Minako  
480 Kaido, Yoko Ogawa, Yukihiro Matsumoto, Ayako Igarashi, Reiko Ishida, Jun Shimazaki, Cristina  
481 Schnider, Kazuno Negishi, Chikako Katakami, Kazuo Tsubota. The Role of Oxidative Stress and  
482 Inflammation in Conjunctivochalasis. *Invest Ophthalmol Vis Sci*. 2010; 51:1994–2002.
- 483 6. Daniel Meller, Steven L. Maskin, Renato T.F. Pires, Scheffer C.G. Tseng. Amniotic Membrane  
484 Transplantation for Symptomatic Conjunctivochalasis Refractory to Medical Treatments. *Cornea*  
485 2000;19(6): 796–803.
- 486 7. I C Francis, D G Chan, P Kim, G Wilcsek, M Filipic, J Yong, M T Coroneo. Case-controlled  
487 clinical and histopathological study of conjunctivochalasis *Br J Ophthalmol* 2005;89:302–305.
- 488 8. Hughes WL. Conjunctivochalasis. *Am J Ophthalmol*. 1942;25: 48 –51.
- 489 9. Yan Wang, Murat Dogru, Yukihiro Matsumoto, Samantha K. Ward, Igarashi Ayako, Yiqian Hu,  
490 Naoko Okada, Yoko Ogawa, Jun Shimazaki, And Kazuo Tsubota. The Impact of Nasal  
491 Conjunctivochalasis on Tear Functions and Ocular Surface Findings. *Am J Ophthalmol* 2007;144:930–  
492 937.
- 493 10. M A Di Pascuale, E M Espana, T Kawakita, S C G Tseng. Clinical characteristics of  
494 conjunctivochalasis with or without aqueous tear deficiency. *Br J Ophthalmol* 2004;88:388–392.
- 495 11. Mimura T, Yamagami S, Usui T, et al. Changes of conjunctivochalasis with age in a hospital-  
496 based study. *Am J Ophthalmol*. 2009; 147(1):171–177-1.
- 497 12. Hughes WL. Conjunctivochalasis. *Am J Ophthalmol*. 1942;25: 48 –51.
- 498 13. Li D-Q, Meller D, Liu Y. Overexpression of MMP-1 and MMP-3 cultured conjunctivochalasis  
499 fibroblasts. *Invest Ophthalmol Vis Sci* 2000;41:404–10.
- 500 14. Tulvatana W, Bhattarakosol P, Sansopha L. Risk factors for conjunctival squamous cell  
501 neoplasia: a matched case-control study. *Br J Ophthalmol* 2003;87:396–8.
- 502 15. Sandra Flavia Fiorentini de Almeida, Luciene B. de Sousa, Luis A. Vieira, Maria I. Chiamollera,  
503 Jeison de N. Barros. Clinic-Cytologic Study of Conjunctivochalasis and Its Relation to Thyroid  
504 Autoimmune Diseases *Cornea* 2006; 25:789–793.



- 505 16. Hoh H, Schirra F, Kienecker C, et al. Lidparallele konjunktivale Falten (LIPCOF) sind ein  
506 sicheres diagnostisches Zeichen des trockenen Auges. *Ophthalmologie* 1995;92:802–13.
- 507 17. Francis IC, Chan DG, Kim P, Wilcsek G, Filipic M, Yong J, Coroneo MT. Case-controlled clinical  
508 and histopathological study of conjunctivochalasis. *British J Ophthalmology*. 2005 Mar;89(3):302-5.
- 509 18. Harbiyeli II, Erdem E, Erdogan S, Kuyucu Y, Polat S, Yagmur M. Investigation of  
510 conjunctivochalasis histopathology with light and electron microscopy in patients with  
511 conjunctivochalasis in different locations. *International Ophthalmology*. 2019 Jul;39(7):1491-1499.
- 512 19. Kalin NS, Orlin SE, Wulc AE. Chronic localized conjunctival chemosis. *Cornea* 1996;15:295–  
513 300.
- 514 20. Ahmad Kheirkhah, Victoria Casas, Salomon Esquenazi,, Gabriela Blanco, Wei Li, V.-K. Raju,  
515 Scheffer C. G. Tseng. New Surgical Approach for Superior Conjunctivochalasis. *Cornea* 2007;26:685–  
516 691.
- 517 21. Gerd Geerling, Würzburg, Horst Brewitt. *Surgery for the Dry Eye*. Karger 2008; 159-162.
- 518 22. Meller D, Li DQ, Tseng SC. Regulation of collagenase, stromelysin and gelatinase B in human  
519 conjunctival and conjunctivochalasis fibroblasts by interleukin-1 and tumor necrosis factor-. *Invest*  
520 *Ophthalmol Vis Sci*. 2000;41(10):2922–2929.
- 521 23. Murakami K, Inagaki J, Saito M, et al. Skin atrophy in cytoplasmic SOD-deficient mice and its  
522 complete recovery using a vitamin C derivative. *Biochem Biophys Res Commun*. 2009;382(2):457–  
523 461.
- 524 24. Acera A, Vecino E, Duran JA. Tear MMP-9 levels as a marker of ocular surface inflammation in  
525 conjunctivochalasis. *Investigative Ophthalmology & Visual Science*. 2013 Dec 23;54(13):8285-91.
- 526 25. Jia YL, Liu XJ, Wen H, Zhan YP, Xiang MH. The expression of MAPK signaling pathways in  
527 conjunctivochalasis. *International J Ophthalmology*. 2019 Nov 18;12(11):1801-1806.
- 528 26. Li DQ, Meller D, Liu Y, Tseng SC. Overexpression of MMP-1 and MMP-3 by cultured  
529 conjunctivochalasis fibroblasts. *Investigative Ophthalmology & Visual Science*. 2000 Feb;41(2):404-  
530 10.
- 531 27. Gan JY, Li QS, Zhang ZY, Zhang W, Zhang XR1. The role of elastic fibers in pathogenesis of  
532 conjunctivochalasis. *International J Ophthalmology*. 2017 Sep 18;10(9):1465-1473.
- 533 28. Gerd Geerling, Würzburg, Horst Brewitt. *Surgery for the Dry Eye*. Karger 2008; 159-162.
- 534 29. Denti AV. Sulla formazione di una plica della congiuntiva bulbare. *Boll Spec Med Chi*.  
535 1930;4:26–32.
- 536 30. Poh S, Lee R, Gao J, Tan C, Gupta P, Sabanayagam C, Cheng CY, Wong TY, Tong L. Factors that  
537 influence tear meniscus area and conjunctivochalasis: The Singapore Indian eye study. *Ophthalmic*  
538 *Epidemiol*. 2018 Feb;25(1):70-78.
- 539 31. Hashemian H, Mahbod M, Amoli FA, Kiarudi MY, Jabbarvand M, Kheirkhah A. Histopathology  
540 of Conjunctivochalasis Compared to Normal Conjunctiva. *J Ophthalmic Vis Res*. 2016 Oct-  
541 Dec;11(4):345-349.
- 542 32. Akihide Watanabe, Norihiko Yokoi, Shigeru Kinoshita, Yoko Hino, Yasunari Tsuchihashi.  
543 Clinicopathologic Study of Conjunctivochalasis *Cornea* 2004;23:294–298.

- 544 33. I C Francis, D G Chan, P Kim, G Wilcsek, M Filipic, J Yong, M T Coroneo. Case-controlled  
545 clinical and histopathological study of conjunctivochalasis Br J Ophthalmol 2005;89:302–305.
- 546 34. Daniel Meller, Steven L. Maskin, Renato T.F. Pires, Scheffer C.G. Tseng. Amniotic Membrane  
547 Transplantation for Symptomatic Conjunctivochalasis Refractory to Medical Treatments. Cornea  
548 2000;19(6): 796–803.
- 549 35. I C Francis, D G Chan, P Kim, G Wilcsek, M Filipic, J Yong, M T Coroneo. Case-controlled  
550 clinical and histopathological study of conjunctivochalasis Br J Ophthalmol 2005;89:302–305.
- 551 36. Yokoi N, Komuro A, Maruyama K, et al. New surgical treatment for superior limbic  
552 keratoconjunctivitis and its association with conjunctivochalasis. Am J Ophthalmol. 2003;135:303–  
553 308.
- 554 37. Ostler HB. Superior limbic keratoconjunctivitis. In: Smolin G, Thoft RA. The Cornea. Boston:  
555 Little Brown; 1987:296–298.
- 556 38. Gumus K, Crockett CH, Pflugfelder SC. Anterior segment optical coherence tomography: a  
557 diagnostic instrument for conjunctivochalasis. Am J Ophthalmol. 2010 Dec;150(6):798-806.
- 558 39. Dalianis G, Trivli A, Terzidou C. The Location of Conjunctivochalasis and Its Clinical Correlation  
559 with the Severity of Dry Eye Symptoms. Medicines (Basel). 2018 Jan 22;5(1).
- 560 40. Meller D, Tseng SC. Conjunctivochalasis: Literature review and possible pathophysiology.  
561 Surv Ophthalmol 1998;43:3:225.
- 562 41. Hughes, W.L. Conjunctivochalasis. Am. J. Ophthalmol. 1942, 25, 48–51.
- 563 42. Otaka, I.; Kyu, N. A new surgical technique for management of conjunctivochalasis. Am. J.  
564 Ophthalmol. 2000, 129, 385–387.
- 565 43. Yang, H.S.; Choi, S. New approach for conjunctivochalasis using an argon green laser. Cornea  
566 2013, 32, 574–578.
- 567 44. Zhang, X.-R.; Zhang, Z.-Y.; Hoffman, M.R. Electrocoagulative Surgical Procedure for Treatment  
568 of Conjunctivochalasis. Int. Surg. 2012, 97, 90–93.
- 569 45. Trivli A., Dalianis G, Terzidou C, A Quick Surgical Treatment of Conjunctivochalasis Using  
570 Radiofrequencies. Healthcare (Basel). 2018 Mar; 6(1): 14.
- 571 46. Nakasato S, Uemoto R, Mizuki N. Thermocautery for inferior conjunctivochalasis. Cornea  
572 2012;31:5:514-9.
- 573 47. Arenas E, Muñoz D. A new surgical approach for the treatment of conjunctivochalasis:  
574 Reduction of the conjunctival fold with bipolar electrocautery forceps. Scientific World Journal  
575 2016;2016:6589751.
- 576 48. Nakasato S, Uemoto R, Mizuki N. Thermocautery for inferior conjunctivochalasis. Cornea.  
577 2012 May;31(5):514-9.
- 578 49. Chan TC, Ye C, Ng PK, Li EY, Yuen HK, Jhanji V. Change in Tear Film Lipid Layer Thickness,  
579 Corneal Thickness, Volume and Topography after Superficial Cauterization for Conjunctivochalasis.  
580 Scientific Reports. 2015 Jul 17;5:12239.
- 581 50. Kim KH, Ko AY, Ryu JS, Kim MK, Wee WR. Effect of electrocauterization on the inflammation  
582 of the conjunctiva in experimental animal model. Korean J Ophthalmology. 2013 Aug;27(4):282-7.

- 583 51. Jiang LH, Zhang XR, Zhang JH, Ying J, Shi C, Li QS. The clinical observation of  
584 conjunctivochalasis crescent conjunctival resection with bipolar coagulation. *Zhonghua Yan Ke Za Zhi*.  
585 2012 May;48(5):409-12.
- 586 52. Haefliger IO, Vysniauskiene I, Figueiredo AR, Piffaretti JM. Superficial conjunctiva  
587 cauterization to reduce moderate conjunctivochalasis. *Klin Monbl Augenheilkd*. 2007 Apr;224(4):237-  
588 9.
- 589 53. Yang HS, Choi S. New approach for conjunctivochalasis using an argon green laser. *Cornea*  
590 2013;32:5:574-8
- 591 54. Yang J, Chandwani R, Gopinath V, Boyce T, Pflugfelder SC, Huang D, Liu G. Near-infrared  
592 laser thermal conjunctivoplasty. *Scientific Reports*. 2018 Mar 1;8(1):3863.
- 593 55. Erdogan-Poyraz C, Mocan MC, Irkec M, Orhan M. Delayed tear clearance in patients with  
594 conjunctivochalasis is associated with punctal occlusion. *Cornea* 2007;26:3:290-3.
- 595 56. Doss LR, Doss EL, Doss RP. Paste-pinch-cut conjunctivoplasty: Subconjunctival fibrin sealant  
596 injection in the repair of conjunctivochalasis. *Cornea* 2012;31:959-962.
- 597 57. Serrano F, Mora LM. Conjunctivochalasis: A surgical technique. *Ophthalmic Surg*  
598 1989;20:12:883-4.
- 599 58. Kheirhah A, Casas V, Esquenazi S, Blanco G, Li W, Raju VK, Tseng SC. New surgical approach  
600 for superior conjunctivochalasis. *Cornea*. 2007 Jul;26(6):685-91.
- 601 59. Wang X, Chen F, Tang X. The clinical comparison of conjunctival resection with conjunctival  
602 resection and sclera fixation in the treatment of conjunctivochalasis. *Zhonghua Yan Ke Za Zhi*. 2014  
603 Sep;50(9):687-90.
- 604 60. Santiago E, Yang Y, Conlon R, Compan J, Baig K, Ziai S. Surgical techniques for the treatment  
605 of conjunctivochalasis: paste-pinch-cut conjunctivoplasty versus thermal cautery conjunctivoplasty.  
606 *Canadian J Ophthalmol*. 2017 Jun;52(3):308-312.
- 607 61. Doss LR, Doss EL, Doss RP. Paste-pinch-cut conjunctivoplasty: subconjunctival fibrin sealant  
608 injection in the repair of conjunctivochalasis. *Cornea*. 2012 Aug;31(8):959-62.
- 609 62. Petris CK, Holds JB. Medial conjunctival resection for tearing associated with  
610 conjunctivochalasis. *Ophthalmic Plast Reconstr Surg*. 2013 Jul-Aug;29(4):304-7.
- 611 63. Otaka I, Kyu N. A new surgical technique for management of conjunctivochalasis. *Am J*  
612 *Ophthalmol*. 2000 Mar;129(3):385-7.
- 613 64. Wang S, Ke M, Cai X, Chen X, Yu A, Dai H, Wen X. An improved surgical method to correct  
614 conjunctivochalasis: conjunctival semiperitomy based on corneal limbus with subconjunctival  
615 cauterization. *Canadian J Ophthalmol*. 2012 Oct;47(5):418-22.
- 616 65. Huang Y, Sheha H, Tseng SC. Conjunctivochalasis interferes with tear flow from fornix to tear  
617 meniscus. *Ophthalmology* 2013;120:8:1681-7.
- 618 66. Otaka I, Kyu N. A new surgical technique for management of conjunctivochalasis. *Am J*  
619 *Ophthalmol* 2000;129:3:385-7.
- 620 67. Kheirhah A, Casas V, Blanco G, Li W, Hayashida Y, Chen YT, Tseng SC. Amniotic membrane  
621 transplantation with fibrin glue for conjunctivochalasis. *Am J Ophthalmol* 2007;144:2:311-3.

622 68. Cheng AM, Yin HY, Chen R, Tighe S, Sheha H, Zhao D, Casas V, Tseng SC. Restoration of fornix  
623 tear reservoir in conjunctivochalasis with fornix reconstruction. *Cornea* 2016;35:6:736-40.

624

625

UNDER PEER REVIEW